Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets Zynerba Pharmaceuticals, Inc. ist ein spezialisiertes Pharmaunternehmen. Das Unternehmen beschäftigt sich mit der Entwicklung und Vermarktung transdermaler synthetischer Cannabinoid-Behandlungen für Patienten mit hohem unerfülltem Bedarf. Die Entwicklungspipeline umfasst zwei Produktkandidaten: ZYN002 und ZYN001 Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZYNE shares have increased by 9.0% and is now trading at $4.24. View which stocks have been most impacted by COVID-19. What price target have analysts set for ZYNE Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.84% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected -0.46% of loss in the last five trading sessions. Press Release reported on 04/06/21 that Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conferenc
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is on an absolute roll right now. Indeed, over the past five trading days, ZYNE stock has nearly doubled. Today, shares of this cannabis-related specialty. Zynerba Pharmaceuticals (ZYNE) stock gained 49 percent on March 15. However, the stock was trading lower by 16 percent in pre-market trading on March 16. What's the forecast for ZYNE stock in 2021?.. Zynerba Pharmaceuticals, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 6 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 2 recommended ZYNE as a Hold, whereas 4 deemed it a Buy, and no one rated it as Underweight. Zynerba. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares, dropped in value on Thursday, Mar 18, with the stock price down by -10.56% to the previous day's close as weak demand from buyers trailed the stock to $4.83. Get the hottest stocks to trade every day before the market opens 100% free
. Improving Connections. Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions The consensus among analysts is that Zynerba Pharmaceuticals, Inc. (ZYNE) is an Overweight stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 7 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non. Zynerba Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company's stock is recorded $9.00 on 02/10/21, with the lowest value was $3.23 for the same time period, recorded on 01/05/21 Real-time trade and investing ideas on Zynerba Pharmaceuticals ZYNE from the largest community of traders and investors. Rooms Shows Rankings Earnings Calendar Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Zynerba Pharmaceuticals 3.97 0.06 (1.49%) Watch. Zynerba Pharmaceuticals NASDAQ Updated Apr 16, 2021 11:49 PM. ZYNE 3.97 0.06 (1.49%) Post-Market 0.02.
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal. Zynerba Pharmaceuticals. stock was originally listed at a price of $16.25 in Aug 5, 2015. If you had invested in Zynerba Pharmaceuticals stock at $16.25, your return over the last 5 years would have been -75.2%, for an annualized return of -24.34% Find the latest press releases from Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com
, company news, press releases, executives, board members, and contact informatio The Zynerba Pharmaceuticals stock price fell by -1.49% on the last day (Friday, 16th Apr 2021) from $4.03 to $3.97. and has now fallen 3 days in a row. During the day the stock fluctuated 3.08% from a day low at $3.90 to a day high of $4.02. The price has fallen in 7 of the last 10 days and is down by -16.95% for this period. Volume fell on the last day along with the stock, which is actually. Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common. Zynerba Pharmaceuticals Inc. [NASDAQ: ZYNE] gained 49.26% on the last trading session, reaching $7.03 price per share at the time. The company report on March 10, 2021 that Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights.. Get the hottest stocks to trade every day before the market opens 100% free Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the.
Zynerba Pharmaceuticals (ZYNE) In a report issued on December 18, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zynerba Pharmaceuticals, with a price target of $9.00. The company's shares closed last Tuesday at $3.66 Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference Benzinga 30d 66 Biggest Movers From Yesterday Gainers SunLink Health Systems, Inc. (NYSE: SSY) shares climbed 151.3%..
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is on an absolute roll right now. Indeed, over the past five trading days, ZYNE stock has nearly doubled. Today, shares of this cannabis-related specialty. Zynerba Pharma Aktie (ZYNE) mit Realtime-Aktienkurs, Chart, Bilanzinformationen, Dividenden, historischen Daten, aktuellen News und Analysen
6 Wall Street analysts have issued ratings and price targets for Zynerba Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.04, predicting that the stock has a possible upside of 224.29%. The high price target for ZYNE is $26.00 and the low price target for ZYNE is $7.25 4 Jan 21 Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences 17 Dec 20 Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome 4 Dec 20 Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES Zynerba Pharmaceuticals Inc (ZYNE) stock has fallen -56.94% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver's proprietary ranking system, gives ZYNE stock a score of 35 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 2 Zynerba Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Zynerba Pharmaceuticals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Zynerba Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Zynerba Pharmaceuticals's ZYNE shares and potentially its market environment have been in. Why Zynerba Pharmaceuticals Stock Is Crashing Today Investors appear to be worried about potential safety issues with its cannabinoid gel. Keith Speights (TMFFishBiz) Sep 18, 2019 at 11:50AM.
View the real-time ZYNE price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Zynerba Pharmaceuticals against related stocks people have also bought like SPPI, AGEN, CPRX, and LLNW Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile. View the latest Zynerba Pharmaceuticals Inc. (ZYNE) stock price, news, historical charts, analyst ratings and financial information from WSJ
Zynerba Pharmaceuticals is a biopharmaceutical company that develops transdermal cannabinoid therapies for the treatment of rare diseases. Conditions include Fragile X syndrome, types of epilepsy, and tourettes. Several products are in the preclinical stages of development. Founded in 2007, Zynerba Pharmaceuticals is based in Pennsylvania, US Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7% (Zacks) 17.09.20 Zynerba Pharmaceuticals cheers FDA decision to grant orphan drug designation for CBD to treat 22q deletion syndrome. ., July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Zynerba Get instant access to a free live streaming chart of the Zynerba Pharmaceuticals Inc Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area. Current stock quote for Zynerba Pharmaceuticals Inc. ( ZYNE ) including financial statements, level 2 data, and the latest Drug Manufacturers - Major news, research, and investment community discussio
A high-level overview of Zynerba Pharmaceuticals, Inc. (ZYNE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools Why Zynerba Pharmaceuticals Stock Zoomed Higher Today . finance . 1 year ago. ZYNE . Zynerba Pharmaceuticals . 1 year ago - finance . Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS) finance . 1. Zynerba Pharmaceuticals Stock Price . Follow ZYNE. 3.95-0.08 (-1.99%) Upgrade to Real-Time Afterhours (Closed) Low 2.80. 52 Week Range. High 9.00. Best deals to access real time data! Big Cap Pro. Monthly Subscription. for only. $52.04. Free trial. Small Cap Basic. Monthly Subscription. for only. $33.03 . Free trial. Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex. Zynerba Pharmaceuticals Inc ZYNE Morningstar Rating Rating as of Apr 16, 2021. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends. Zynerba Pharmaceuticals, Inc. ist ein spezialisiertes Pharmaunternehmen. Das Unternehmen beschäftigt sich mit der Entwicklung und Vermarktung transdermaler synthetischer Cannabinoid-Behandlungen für Patienten mit hohem unerfülltem Bedarf. Die Entwicklungspipeline umfasst zwei Produktkandidaten: ZYN002 und ZYN001. ZYN002 ist ein synthetisches Cannabidiol (CBD), ein nicht-psychotaktives.
In depth view into ZYNE (Zynerba Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes. Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7% - September 18.
Zynerba Pharmaceuticals (ZYNE Quick Quote ZYNE - Free Report) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.This change lagged the S&P 500's 1.95% gain on. Is Zynerba Pharmaceuticals a good stock to buy now?ZYNE investors should be aware of a decrease in hedge fund interest recently. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) was in 7 hedge funds. Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients Sep. 24, 2020 2:52 PM ET Zynerba Pharmaceuticals, Inc. (ZYNE) 2 Comments 3 Likes Faizan Muhamma Zynerba Pharmaceuticals (NASDAQ:ZYNE) belongs to the last kind of marijuana stock. Like other cannabis-focused biotechs, Zynerba really doesn't develop drugs made from marijuana plants but instead.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental. Armando Anido has been the CEO of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) since 2014, and this article will examine the executive's compensation with respect to the overall performance of the company.This analysis will also assess whether Zynerba Pharmaceuticals pays its CEO appropriately, considering recent earnings growth and total shareholder returns
Zynerba Pharmaceuticals, Inc. has a 12 month low of $3.12 and a 12 month high of $9.00. The stock has a market cap of $170.37 million, a PE ratio of -2.23 and a beta of 2.83. The company has a 50-day moving average price of $4.68 and a 200 day moving average price of $4.13 . [NASDAQ: ZYNE] gained 12.64% or 0.57 points to close at $5.08 with a heavy trading volume of 21493283 shares. The company report on January 4, 2021 that Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences.. Get the hottest stocks to trade every day before the market opens 100% free Zynerba stock forecast for 20.04.2021. Estimated Average Forecasted Zynerba Price: 4.51 Positive intraday dynamics of the instrument is expected with 6.482% volatility is expected. Pessimistic forecast: 4.33 Optimistic: 4.63 Zynerba stock forecast for 21.04.2021
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) (FRA:6ZY) is a pharmaceutical company focused on developing and marketing synthetic cannabinoid therapeutics for transdermal delivery. These therapetics seek to meet the unmet needs of patients with epilepsy, osteoarthritis, fibromyalgia, peripheral neuropathic pain, and Fragile X syndrome. Zynerba's. Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is. Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) stock closed at 4.28 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 821.35K shares and market capitalization of 167.48M. Is a component of indices and it is traded on NASDAQ exchange ZYNE, $ZYNE, Zynerba Pharmaceuticals Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis.
.C. Wainwright maintained a Buy rating on Zynerba Pharmaceuticals, with a price target of $9.00. The company's shares closed last Friday at $3.40. According to TipRanks.com, Livnat is a 4-star analyst with an average return of 10.6% and a 50.4% success rate. Livnat. Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET Zynerba Pharmaceuticals Inc is a small-cap biotech stock that develops CBD therapies to treat rare diseases. The overlooked development-stage company was the top-performing cannabis stock in the. Zynerba Pharmaceuticals, Inc () Stock Market info Recommendations: Buy or sell Zynerba Pharmaceuticals stock? Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Zynerba Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Zynerba Pharmaceuticals's 6ZY shares and potentially its market environment have been in a.
Zynerba Pharmaceuticals To Present At The 19th Annual Needham Virtual Healthcare Conference. By GlobeNewswire . Apr 10, 2020 8:00 AM EDT. JIM CRAMER. Big Victory for the Bulls: Cramer's 'Mad Money. Dienstag, 30.06.2020 - 15:00 Uhr - Chartanalyse HotStocks USA: -39% bei ZYNERBA PHARMA Anbei erhalten Sie eine Übersicht über die Werte, die vorbörslich an der Nasdaq am meisten. Zynerba Pharmaceuticals stock research in summary. zynerba.com. There is no stock research analysis by the purely financial fact-based Obermatt method for: Zynerba Pharmaceuticals (NasdaqGM:ZYNE), Pharmaceuticals, USA. Contact us if you would like research on this stock Thinking about buying stock in Zomedica Pharmaceuticals, Nio Inc, Advanced Micro Devices, Norwegian Cruise Line, or Zynerba Pharmaceuticals? PR Newswire PR Newswire 11.12.19 - PR Newswir Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know. Read full article. Zacks Equity Research. 29 July 2020, 5:50 pm · 2-min read. Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.24%. Elsewhere, the Dow gained 0.61%, while the tech-heavy.